Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EPS (Basic) (2016 - 2025)

Rocket Pharmaceuticals' EPS (Basic) history spans 10 years, with the latest figure at -$0.38 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 38.71% year-over-year to -$0.38; the TTM value through Dec 2025 reached -$2.01, up 26.37%, while the annual FY2025 figure was -$2.01, 26.37% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.38 at Rocket Pharmaceuticals, up from -$0.45 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.38 in Q4 2025 and bottomed at -$0.89 in Q4 2022.
  • The 5-year median for EPS (Basic) is -$0.68 (2021), against an average of -$0.68.
  • The largest annual shift saw EPS (Basic) crashed 50.91% in 2022 before it skyrocketed 38.71% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.68 in 2021, then tumbled by 30.88% to -$0.89 in 2022, then skyrocketed by 30.34% to -$0.62 in 2023, then changed by 0.0% to -$0.62 in 2024, then surged by 38.71% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's EPS (Basic) are -$0.38 (Q4 2025), -$0.45 (Q3 2025), and -$0.62 (Q2 2025).